About: Short- and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Short- and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Short- and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode
Creator	Vuorinen, Tytti Jartti, Tuomas Ruuskanen, Olli Lehtinen, Pasi Gern, James Vahlberg, Tero Camargo, Carlos Finland, Madison, Nieminen, Riitta Wis, Boston
Source	Elsevier; Medline; PMC
abstract	Background Rhinovirus-induced wheezing is an important risk factor for recurrent wheezing. There are no randomized controlled trials on the effect of systemic corticosteroids in patients with this disease. Objective We sought to study the short- and long-term effects of prednisolone treatment of the first acute, moderate-to-severe, rhinovirus-induced wheezing episode in young children. Methods After confirming rhinovirus from nasopharyngeal aspirate by using PCR, 79 children with a first wheezing episode at age 3 to 23 months were randomized to receive oral prednisolone (first dose of 2 mg/kg, followed by 2 mg/kg/d in 2 divided doses for 3 days) or placebo. The trial was double blind throughout the 12-month follow-up. The primary outcomes were long term: new physician-confirmed wheezing episode within 2 months, number of physician-confirmed wheezing episodes within 12 months, and initiation of regular controller medication for asthma symptoms within 12 months. The primary interaction analysis examined rhinovirus load. Results Seventy-four patients completed the study (mean age, 13 months; 28% atopic). Long-term outcomes did not differ between groups (all P ≥ .30). For short-term outcomes, the prednisolone group had less cough, rhinitis, noisy breathing, severe breathing difficulties, and nocturnal respiratory symptoms at home within 2 weeks (all P < .05). The 25 children with greater than 7000 rhinovirus copies/mL (most sensitive cutoff) benefitted from prednisolone in terms of less risk of physician-confirmed recurrence within 2 and 12 months compared with placebo (both P < .05). Conclusions Prednisolone cannot be routinely recommended for all young children experiencing their first acute, moderate-to-severe, rhinovirus-induced wheezing episode. Prednisolone might be beneficial in a subgroup of children with high viral loads.
has issue date	2015-03-31(xsd:dateTime)
bibo:doi	10.1016/j.jaci.2014.07.001
bibo:pmid	25129681
has license	els-covid
sha1sum (hex)	28bfd55cd477029dab0e713bba17caa5da31ca55
schema:url	https://doi.org/10.1016/j.jaci.2014.07.001
resource representing a document's title	Short- and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode
has PubMed Central identifier	PMC7112325
has PubMed identifier	25129681
schema:publication	Journal of Allergy and Clinical Immunology
resource representing a document's body	covid:28bfd55cd477029dab0e713bba17caa5da31ca55#body_text
is schema:about of	named entity 'INDUCED' named entity 'group' named entity 'randomized controlled trials' named entity 'systemic' named entity 'groups' named entity 'study' named entity 'weeks' named entity 'wheezing' named entity 'efficacy' named entity 'SHORT' named entity 'CONTROLLER' named entity 'METHODS' named entity 'INTERACTION' named entity 'LOAD' named entity 'CUTOFF' named entity 'OBJECTIVE' named entity 'DOSES' named entity 'SYSTEMIC' named entity 'RHINOVIRUS' named entity 'RHINITIS' named entity 'CORTICOSTEROIDS' named entity 'SHORT-TERM' named entity 'IMMUNOL' named entity 'SENSITIVE' named entity 'CONFIRMING' named entity 'MEDICATION' named entity 'HIGH' named entity 'WHEEZING' named entity 'RISK OF' named entity '7000' named entity 'IMPORTANT' named entity 'RANDOMIZED CONTROLLED TRIALS' named entity 'OUTCOMES' named entity 'CONFIRMED' named entity '12 MONTHS' named entity 'NOISY BREATHING' named entity 'AT HOME' named entity 'WHEEZING' named entity 'LONG-TERM' named entity 'RECURRENCE' covid:arg/28bfd55cd477029dab0e713bba17caa5da31ca55 named entity 'EFFICACY' named entity 'MODERATE-TO-SEVERE' named entity 'RISK FACTOR' named entity 'SUBGROUP' named entity 'FOLLOWED BY' named entity 'RECEIVE' named entity 'COUGH' named entity 'PREDNISOLONE' named entity 'EPISODE' named entity 'ACUTE' named entity 'DISEASE' named entity 'DAYS' named entity 'EXAMINED' named entity 'ACUTE' named entity 'VIRAL' named entity 'BREATHING DIFFICULTIES' named entity 'YOUNG CHILDREN' named entity 'PRIMARY' named entity 'RECURRENT' named entity 'RANDOMIZED' named entity 'CHILDREN' named entity 'PREDNISOLONE' named entity 'ANALYSIS' named entity 'COPIES' named entity 'RESULTS' named entity 'MONTHS' named entity 'TERMS' named entity 'SEVERE' named entity '2 WEEKS' named entity 'RHINOVIRUS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software